Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 25, 2015 12:52 AM ET


Company Overview of Celladon Corporation

Company Overview

Celladon Corporation, a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. The company’s lead product candidate includes MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heart. Its MYDICAR product is used to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, as well as to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure. The company is also developing membrane-bound form of Stem Cell Factor for the treat...

11988 El Camino Real

Suite 650

San Diego, CA 92130

United States

Founded in 2000

34 Employees





Key Executives for Celladon Corporation

Chief Executive Officer and Director
Age: 58
Total Annual Compensation: $479.3K
President and Chief Financial Officer
Age: 57
Total Annual Compensation: $189.7K
Vice President, General Counsel and Secretary
Age: 43
Total Annual Compensation: $233.8K
Vice President of Corporate Development & Investor Relations
Age: 43
Total Annual Compensation: $190.4K
Vice President of Corporate Operations
Age: 53
Total Annual Compensation: $216.3K
Compensation as of Fiscal Year 2014.

Celladon Corporation Key Developments

Celladon Corporation Announces Un-Audited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Celladon Corporation announced un-audited consolidated earnings results for the first quarter ended March 31, 2015. The company reported loss from operations of $16.3 million compared to $6.9 million and net loss of $16.7 million compared to $7.2 million for the last year.

Celladon Explores Strategic Options

Celladon Corporation (NasdaqGM:CLDN) is exploring strategic options. Krisztina Zsebo, Chief Executive Officer of Celladon, said, "We are evaluating our strategic options in order to determine the best path forward to maximize shareholder value."

Celladon Corporation - Special Call

To discuss negative results for CUPID2 trial of MYDICAR(R) in advanced heart failure

Similar Private Companies By Industry

Company Name Region
Integral Molecular, Inc. United States
NeuroCorp., Ltd. United States
Bio-Tissue, Inc. United States
Natural Industries, Inc. United States
Visterra, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Celladon Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at